NPAS4 has been proposed as a novel therapeutic target for depression and neurodegenerative diseases associated with synaptic dysfunction (9), as a component of new stroke therapies (10), as a therapeutic target for diabetes (11), and as a treatment during pancreas transplantation (12). Here, NPAS4 is linked to depressive symptom measurement.